BUFFALO, NY--(Marketwire - January 5, 2010) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today
announced that the Company is scheduled to present at the OneMedForum 2010,
January 12-13, in San Francisco, CA.
Michael Fonstein, Ph.D., Chief Executive Officer and President of Cleveland
BioLabs, will give a presentation on January 13, at 3:15 p.m. Pacific
Standard Time / 6:15 p.m. Eastern Standard Time. An audio webcast of the
presentation may be accessed at http://www.onemedplace.com/. The
presentation will be archived at this location for three months.
Cleveland BioLabs is developing a pipeline of products for multiple defense
and medical applications from two primary families of compounds: Protectans
and Curaxins. Protectans are being developed as drug candidates that
protect normal tissues from acute stresses such as radiation and
chemotherapy. Curaxins are being developed as anticancer agents that could
act as mono-therapy drugs or in combination with other existing anticancer
The Company recently announced the opening of enrollment for the second
human safety study for CBLB502, a drug under development for the treatment
of Acute Radiation Syndrome (ARS).
CBLB502 is being developed by Cleveland BioLabs under the U.S. Food and
Drug Administration's Animal Efficacy Rule to treat Acute Radiation
Syndrome (ARS) or radiation poisoning from any exposure to radiation such
as a nuclear or radiological weapon / dirty bomb, or from a nuclear
accident. This approval pathway requires demonstration of efficacy in
representative animal models and safety and drug metabolism testing in
healthy human volunteers.
For more information about the OneMedForum, please refer to:
About Cleveland BioLabs, Inc.
Cleveland BioLabs, Inc. is a drug discovery and development company
leveraging its proprietary discoveries around programmed cell death to
develop treatments for cancer and protection of normal tissues from
exposure to radiation and other stresses. The Company has strategic
partnerships with the Cleveland Clinic, Roswell Park Cancer Institute,
ChemBridge Corporation and the Armed Forces Radiobiology Research
Institute. To learn more about Cleveland BioLabs, Inc., please visit the
company's website at http://www.cbiolabs.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of
this press release, and involve certain risks and uncertainties. The
Company's actual results could differ materially from those anticipated in
these forward-looking statements as a result of various factors. Some of
the factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the
"Risk Factors" described in the Company's Annual Report on Form 10-K filed
with the Securities and Exchange Commission on March 30, 2009.
Contact Information: Contact:
Director Corporate Development & Communications
Cleveland BioLabs, Inc.
T: (646) 284-9439